Real-world effectiveness and safety of upadacitinib in difficult-to-treat Crohn's disease: a multicenter study in China
10.3760/cma.j.cn101480-20250809-00118
- VernacularTitle:乌帕替尼治疗难治性克罗恩病的疗效与安全性：一项中国的多中心研究
- Author:
Zile ZHANG
1
;
Shuowen ZHANG
;
Wensong GE
;
Yue LI
;
Ruidong CHEN
;
Wen TANG
;
Qunying WANG
;
Yihong FAN
;
Linyan ZHOU
;
Feng TIAN
;
Chunxiao CHEN
;
Yubei GU
;
Duowu ZOU
Author Information
1. 上海交通大学医学院，上海 200025
- Publication Type:Journal Article
- Keywords:
Difficult-to-treat Crohn's disease;
Upadacitinib;
Efficacy;
Safety
- From:
Chinese Journal of Inflammatory Bowel Diseases
2025;09(6):443-447
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of upadacitinib in the real-world treatment of difficult-to-treat Crohn's disease (DTT-CD) .Methods:This multicenter, retrospective cohort study included patients diagnosed with DTT-CD according to the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) criteria, and treated at eight Chinese inflammatory bowel disease centers between January 2023 and March 2025. Clinical outcomes were assessed after 12 weeks of induction therapy with upadacitinib (45 mg qd), including clinical remission rate, clinical response rate, and incidence of adverse events.Results:Among 151 enrolled DTT-CD patients, the clinical remission rate was 47.0%, and the clinical response rate was 90.7% after 12 weeks of treatment. Adverse events occurred in 42 cases (27.8%) .Conclusion:Upadacitinib demonstrated favorable efficacy in inducing clinical remission in DTT-CD patients, with a good safety profile at the induction dose (45 mg qd) .
